Table 3.
Treatments and Prognosis Outcomes in Patients with COVID-19
| Treatments and Prognosis Outcomes | Total (N = 46) | Adolescents (n = 14) | Young Adults (n = 32) | p Value |
|---|---|---|---|---|
| Complications | ||||
| Acute kidney injury | 3 (6.5) | 1 (7.1) | 2 (6.3) | 0.99 |
| Treatments | 0.63 | |||
| Antiviral therapy | 46 (100.0) | 14 (100.0) | 32 (100.0) | – |
| Antifungal treatment | 5 (10.9) | 2 (14.3) | 3 (9.4) | 0.63 |
| Oxygen inhalation | 39 (84.8) | 9 (64.3) | 30 (93.8) | 0.02 |
| Atomization inhalation treatment | ||||
| Interferon-α | 43 (93.5) | 13 (92.9) | 30 (93.8) | 0.67 |
| N-Acetylcysteine + interferon-α | 1 (2.2) | 0 (0.0) | 1 (3.1) | |
| N-Acetylcysteine + budesonide + interferon-α | 2 (4.4) | 1 (7.1) | 1 (3.1) | |
| Days of persistent fever during admission, median (IQR) | 5 (1.0–8.0) | 4.5 (0.0–7.0) | 5 (2.0–9.0) | 0.43 |
| Days from date of admission to date of presenting negative result of COVID-19 nucleic acid test, median (IQR) | 12.5 (8.0–16.0) | 13.0 (8.0–16.0) | 12.50 (8.5–15.5) | 0.87 |
| Prognosis | 0.07 | |||
| Hospital admission | 10 (21.7) | 2 (14.3) | 8 (25.0) | |
| Recovered and discharged | 36 (78.3) | 12 (85.7) | 24 (75.0) | |
Values are number (%) unless stated otherwise.